Jyong Biotech Ltd. (MENS)

NASDAQ: MENS · USD

$1.97

+0.06 (+3.1%)· Recorded snapshot

Market cap	146.2M
Net income (ttm)	-4.7M
EPS (ttm)	-$0.06
Shares out	74.2M
Volume	11,935

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -4.7M
EPS (ttm): -$0.06
Market cap: 146.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All MENS indicators

Market & fundamental data

Available fields

150

Groups with data

Currency

USD

Showing 150 of 150 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001954488
Company name	Jyong Biotech Ltd.
Country	Taiwan
Country code	US
CUSIP number	G83116106
Earnings date	2026-11-20
Earnings time	bmo
Employees	27
Employees change	0
Employees growth	0%
Enterprise value	$163.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2025-12-31
First seen	2026-05-09
Fiscal year end	December
Founded	2002
Industry	Biotechnology
IPO date	2025-06-17
Is primary listing	Yes
Is SPAC	No
ISIN number	KYG831161065
Last 10-K release date	2026-05-15
Last earnings date	2026-05-15
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$146.2M
Market cap category	Micro-Cap
Next earnings date	2026-11-20
Options	Yes
Price	$1.97
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	MENS
Website	https://jyongbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-3.25%
FCF / EV yield	-1.95%
FCF yield	-2.19%
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-173,000
ROA	-12.01%
ROA (5Y)	-16.62%
ROCE	18.58%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$100,000
EBIT	$-2.6M
EBITDA	$-2.5M
EPS	$-0.06
FCF per share	$-0.04
Financing cash flow	$17.6M
Free cash flow	$-3M
Investing cash flow	$-13.5M
Net borrowing	$-24,000
Net cash flow	$1.1M
Net income	$-4.7M
Operating income	$-2.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$-0.34
Interest coverage	-1.03
Long-term assets	$5.2M
Long-term liabilities	$10.9M
Net cash (debt)	$-17.4M
Net cash / market cap	-12.52%
Piotroski F-Score	3
Property, plant and equipment	$3.2M
Shareholders' equity	$-24.9M
Tangible book value	$-24.9M
Tangible book value per share	$-0.34
Total assets	$20.8M
Total cash	$1.2M
Total debt	$18.5M
Total liabilities	$45.7M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$15.5M
Current liabilities	$34.8M
Current ratio	0.45
Net working capital	$-12.1M
Quick ratio	0.03
Working capital	$-19.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.02%
Dividend yield	0%
Shareholder yield	-2.02%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.13
1D price change	3.14%
1M price change	-1.35%
1M total return	-1.35%
1W price change	7.67%
1W total return	7.67%
1Y price change	-95.99%
1Y return CAGR	-96%
1Y total return	-95.99%
20-day SMA	$1.97
200-day SMA	$2.17
3M price change	-17.59%
3M total return	-17.59%
50-day SMA	$2.08
50-day SMA vs 200-day SMA	50under200
52-week high	$52.01
52-week high date	2025-10-30
52-week low	$1.43
52-week low date	2026-02-11
6M price change	-6.86%
6M total return	-6.86%
All-time high	$67.00
All-time high date	2025-09-12
All-time low	$1.43
All-time low date	2026-02-11
Average true range (ATR)	$0.17
Average volume	42.1K
Beta (1Y)	1.35
Beta (2Y)	2.29
Change from 52-week high	-96.21%
Change from 52-week low	37.76%
Change from all-time high	-97.01%
Change from all-time low	40.04%
Change from open	0%
Day's gap	3.14%
Dollar volume	$23,512
High price	$1.97
Low price	$1.97
Monthly RSI	47.08
Open price	$1.97
Previous close	$1.91
Price vs 150-day SMA	-5.8%
Price vs 20-day SMA	1.6%
Price vs 200-day SMA	-7.71%
Price vs 50-day SMA	-3.91%
Relative volume	0.28
Return from IPO open	-87.53%
RSI	51.41
Sharpe ratio	-1.01
Sortino ratio	-1.33
Volume	11.9K
Weekly RSI	39.03
YTD price change	-49.3%
YTD total return	-49.3%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	26.9M
Float percentage	36.3%
Shares change (QoQ)	3.49%
Shares change (YoY)	2.02%
Shares held by insiders	63.7%
Shares held by institutions	0.73%
Shares outstanding	74.2M
Short % of float	0.82%
Short % of shares	0.3%
Short ratio	4.4 days

Deeper analysis on MENS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this MENS report

Is a complete MENS research report available?

No complete published report is available for Jyong Biotech Ltd. (MENS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Jyong Biotech Ltd. (MENS)

Price

Financial snapshot

Fair-value bridge

Latest news · MENS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All MENS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on MENS

Frequently asked questions